BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 11940493)

  • 1. Acute myeloid leukemia in the elderly: evaluation of overall survival in 69 consecutive patients.
    Veneri D; Zanetti F; Franchini M; Ambrosetti A; Pizzolo G
    Haematologica; 2002 Apr; 87(4):447-8. PubMed ID: 11940493
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral induction and consolidation chemotherapy with idarubicin and etoposide in elderly patients with acute myeloid leukemia.
    Oriol A; Ribera JM; Brunet S; Esteve J; Bueno J; Llorente A
    Haematologica; 2003 Feb; 88(2):229-30. PubMed ID: 12604418
    [No Abstract]   [Full Text] [Related]  

  • 3. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study.
    Behringer B; Pitako JA; Kunzmann R; Schmoor C; Behringer D; Mertelsmann R; Lübbert M
    Ann Hematol; 2003 Jul; 82(7):381-9. PubMed ID: 12756497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The outcome of intensive induction therapy in patients >or=70 years with acute myeloid leukemia.
    Gupta V; Xu W; Keng C; Alibhai SM; Brandwein J; Schimmer A; Schuh A; Yee K; Minden MD
    Leukemia; 2007 Jun; 21(6):1321-4. PubMed ID: 17344911
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute myeloid leukemia treatment in patients over 60 years of age. Comparison of symptomatic, palliative, and aggressive therapy.
    Doubek M; Palasek I; Brychtova Y; Buchtova I; Mayer J
    Neoplasma; 2005; 52(5):411-4. PubMed ID: 16151586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
    Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia.
    Baz R; Rodriguez C; Fu AZ; Jawde RA; Kalaycio M; Advani A; Sobecks R; Sekeres MA
    Cancer; 2007 Oct; 110(8):1752-9. PubMed ID: 17724726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
    Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal post-remission therapy for flow-cytometry minimal residual disease positive adult patients with acute myeloid leukemia.
    Buccisano F; Maurillo L; Del Poeta G; Gattei V; Amadori S; Venditti A
    Haematologica; 2006 Dec; 91(12 Suppl):ELT14; author reply ELT15. PubMed ID: 17194674
    [No Abstract]   [Full Text] [Related]  

  • 11. 4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia.
    Rizzieri DA; Talbot JT; Long GD; Vredenburgh JJ; Gasparetto C; Smith CS; Colvin MO; Adams D; Morris A; Dodge R; Loftis J; Waters-Pick B; Reese M; Carawan H; Koh LP; Chao NJ
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):183-8. PubMed ID: 12652469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
    Wrzesień-Kuś A; Robak T; Wierzbowska A; Lech-Marańda E; Pluta A; Wawrzyniak E; Krawczyńska A; Kuliczkowski K; Mazur G; Kiebiński M; Dmoszyńska A; Wach M; Hellmann A; Baran W; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S;
    Ann Hematol; 2005 Sep; 84(9):557-64. PubMed ID: 15856358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival of elderly patients with acute myeloid leukemia.
    Pulsoni A; Pagano L; Latagliata R; Casini M; Cerri R; Crugnola M; De Paoli L; Di Bona E; Invernizzi R; Marmont F; Petti MC; Rigolin G; Ronco F; Spadano A; Tosti ME; Visani G; Mele A; Mandelli F
    Haematologica; 2004 Mar; 89(3):296-302. PubMed ID: 15020267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial.
    Thomas X; Elhamri M; Chelghoum Y; Reman O; Arnaud P; Raffoux E; Le QH; Tavernier E; Dombret H; Michallet M
    Ann Hematol; 2005 Jun; 84(6):376-82. PubMed ID: 15782343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I/II study of oral etoposide and idarubicin in elderly patients with high-risk acute myeloid leukemia unable to undergo intensive chemotherapy.
    Fiegl M; Büchner T; Hiddemann W; Braess J
    Ann Hematol; 2005 Apr; 84(4):227-31. PubMed ID: 15517268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology.
    Matsouka P; Pagoni M; Zikos P; Giannakoulas N; Apostolidis I; Asprogeraka T; Arvanitopoulou E; Spanoudakis E; Kotsianidis I; Tsatalas K; Papaioannou M; Marinakis T; Skandali A; Viniou N; Yataganas X; Bakiri M
    Ann Hematol; 2006 Apr; 85(4):250-6. PubMed ID: 16416114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment strategy and long-term results in pediatric patients treated in two consecutive AML-GATLA trials.
    Armendariz H; Barbieri MA; Freigeiro D; Lastiri F; Felice MS; Dibar E
    Leukemia; 2005 Dec; 19(12):2139-42. PubMed ID: 16304573
    [No Abstract]   [Full Text] [Related]  

  • 18. [Efficacy and safety of induction chemotherapy consisting of anthracycline for 3 days and cytarabine for 7 days in elderly patients with acute myeloid leukemia].
    Kurahashi S; Iwasaki T; Suzuki H; Sawamoto A; Sugimoto T; Narimatsu H; Adachi T; Hayakawa F; Sugiura I
    Gan To Kagaku Ryoho; 2007 Oct; 34(10):1617-21. PubMed ID: 17940376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapse and death during first remission in acute myeloid leukemia.
    Yanada M; Garcia-Manero G; Borthakur G; Ravandi F; Kantarjian H; Estey E
    Haematologica; 2008 Apr; 93(4):633-4. PubMed ID: 18379012
    [No Abstract]   [Full Text] [Related]  

  • 20. "3+7" therapy for the treatment of acute myeloid leukemia. CON.
    Estey EH
    Clin Adv Hematol Oncol; 2005 Feb; 3(2):129-132, 141. PubMed ID: 16173152
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.